Michael Z. Gilcrease
MD Anderson Cancer Center
United States of America
Degree-Granting Education:- 1991 :Vanderbilt Medical School, Nashville, TN, USA, MD, Medicine 1989 :Vanderbilt Graduate School, Nashville, TN, USA, PHD, Pathology 1984 :Yale College, New Haven, CT, USA, BA, Religious studies. Postgraduate Training:- 1994-1995 :Clinical Fellowship, Surgical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 1991-1994 :Clinical Residency, Anatomic Pathology, Baylor College of Medicine, Houston, TX.
Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol 26 (7) :1346-52, 2015.
Eghtedari M, Dogan BE, Gilcrease M, Roberts J, Cook ED, Yang WT. Imaging and pathologic characteristics of breast amyloidosis. Breast J 21 (2) :197-9, 2015.
Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology 67 (2) :245-54, 2015.